Favezelimab/Pembrolizumab
- Generic Name
- Favezelimab/Pembrolizumab
A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)
- Conditions
- Neoplasm Metastasis
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06395090
- Locations
- 🇺🇸
Yale-New Haven Hospital ( Site 2012), New Haven, Connecticut, United States
🇺🇸University of Iowa-Holden Comprehensive Cancer Center ( Site 2017), Iowa City, Iowa, United States
🇺🇸Children's Mercy Hospital ( Site 2024), Kansas City, Missouri, United States
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
- Conditions
- Cutaneous Squamous Cell CarcinomaEndometrial CancerSolid Tumor
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT06036836
- Locations
- 🇺🇸
Yale-New Haven Hospital-Yale Cancer Center ( Site 0643), New Haven, Connecticut, United States
🇺🇸Dana-Farber Cancer Institute ( Site 0642), Boston, Massachusetts, United States
🇺🇸Rutgers Cancer Institute of New Jersey ( Site 0635), New Brunswick, New Jersey, United States
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 94
- Registration Number
- NCT05600309
- Locations
- 🇨🇳
Hainan General Hospital ( Site 1177), Haikou, Hainan, China
🇨🇳Fujian Province Cancer Hospital ( Site 1178), Fuzhou, Fujian, China
🇨🇳The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 1159), Guangzhou, Guangdong, China
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05508867
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center ( Site 0500), Guangzhou, Guangdong, China
🇺🇸The University of Arizona Cancer Center - North Campus ( Site 2216), Tucson, Arizona, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica ( Site 2208), Los Angeles, California, United States
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 441
- Registration Number
- NCT05064059
- Locations
- 🇨🇳
Fujian Province Cancer Hospital ( Site 1178), Fuzhou, Fujian, China
🇨🇳Guangxi Medical University Affiliated Tumor Hospital ( Site 1158), Nanning, Guangxi, China
🇨🇳Wuhan Union Hospital Cancer Center ( Site 1162), Wuhan, Hubei, China
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 400
- Registration Number
- NCT04626479
- Locations
- 🇳🇱
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 2402), Amsterdam, Noord-Holland, Netherlands
🇨🇱CIDO SpA-Oncology ( Site 2106), Temuco, Araucania, Chile
🇬🇧The Christie NHS Foundation Trust ( Site 1400), Manchester, United Kingdom
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 370
- Registration Number
- NCT04626518
- Locations
- 🇺🇸
UTSW Medical Center ( Site 3003), Dallas, Texas, United States
🇺🇸University of Chicago ( Site 3013), Chicago, Illinois, United States
🇺🇸Yale-New Haven Hospital-Yale Cancer Center ( Site 3011), New Haven, Connecticut, United States
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 315
- Registration Number
- NCT04305054
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute ( Site 2009), Los Angeles, California, United States
🇺🇸UCLA Hematology & Oncology ( Site 2004), Los Angeles, California, United States
🇺🇸Providence Saint John's Health Center ( Site 2010), Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.